-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Screening for the Biggest Cancer Killer: Beating Lung Cancer Through Screening Guidelines?
Many of Europe’s achievements and commitments have been exemplary in the development of health-related science, technology, and regulation, and the European Union (EU) is on the brink of providing further stimulus both to technology development and to the role of the EU in health policy. There are great expectations of the promised EU Health Data…
-
Management of Breathlessness in Lung Cancer Post-Surgery: An Interview With U.S. and U.K. Nurses
Breathlessness or shortness of breath (SOB) can be a short-term or long-term side effect after surgery, particularly lobectomy, for patients with NSCLC. There is good evidence now to support use of prehabilitation for better outcomes post-surgery. However, the proper management strategy in the postoperative setting has been difficult given lack of good prospective data to…
-
Sotorasib Wins Approval for Unmet Need in KRAS G12C-Driven NSCLC
On May 28, the US Food and Drug Administration (FDA) granted accelerated approval of sotorasib for patients with KRAS G12C-mutated NSCLC who have received at least one prior line of therapy. Previously considered an “undruggable” target, KRAS G12C is the primary driver of approximately 13% of nonsquamous NSCLC. Approval was based on the phase II…
-
Biomarkers May Illuminate the Path Forward for PARP Inhibitors in SCLC
Despite U.S. Food and Drug Administration (FDA) approvals for the addition of anti–programmed death-ligand 1 (PD-L1) therapies to a first-line combination of etoposide plus a platinum-based agent for extensive-stage small cell lung cancer (SCLC).1 ,2 Overall survival (OS) remains poor—roughly 1 year for patients diagnosed with extensive-stage disease. Promising new agents in relapsed disease, such…
-
Approval of Combination Ipilimumab and Nivolumab for Mesothelioma: What Happens Now?
October 2, 2020, saw the first U.S. Food and Drug Administration approval of a drug combination for malignant pleural mesothelioma in 16 years, since the combination cisplatin and pemetrexed was approved for this indication in 2004. During the intervening years, we have witnessed numerous negative clinical trials of drug combinations for this disease, mostly phase…
-
Survivorship in Lung Cancer: An Interview With Dr. Anne Katz
Anne Katz, PhD, RN, FAAN, is a certified sexuality counselor and clinical nurse specialist at Cancer Care Manitoba, Winnipeg, Canada, and the author of multiple books on cancer survivorship. In the following article, Dr. Katz discusses lung cancer survivorship challenges as well as considerations that providers should take to ensure that this population is receiving…
-
Wally Curran Departs Directorship at Emory for a Lead Role with GenesisCare
Walter J. “Wally” Curran, Jr., MD, the first radiation oncologist to serve as director of a National Cancer Institute-designated comprehensive cancer center, stepped down from that role at Emory University’s Winship Cancer Institute in January 2021 to take the reins as global chief medical officer of GenesisCare, which provides radiation oncology, urology, and pulmonary treatments…
-
Dr. Anne-Marie Dingemans Leads EORTC’s Lung Cancer Group
Anne-Marie Dingemans, MD, PhD, was installed in January 2021 as chair of the European Organisation for Research and Treatment of Cancer Lung Cancer Group, filling a role previously held by Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Campus in Paris. Dr. Dingemans has been a pulmonologist and professor at Erasmus Medical Center in…
-
Dr. Marina Garassino Accepts Professorship at University of Chicago
Marina Chiara Garassino, MD, stepped into a role as professor of medicine in the Section of Hematology/Oncology at the University of Chicago Department of Medicine in March 2021, making a move from one of the most renowned comprehensive cancer centers in Italy, the Istituto Nazionale dei Tumori of Milan, where she led the Thoracic Medical Oncology…
-
Leveraging Lung Cancer Screening Scans to Detect Early Interstitial and Obstructive Lung Disease
CT screening for lung cancer can reveal subtle early signs of disease in the lungs that extend beyond potential malignancy. As reviewed by Bram van Ginneken, PhD, of the Radboud University Medical Center in The Netherlands, quantitative measures obtained from a chest CT scan may enable the early detection of different obstructive and interstitial lung…